GMI Human Immunodeficiency Virus (HIV)-1 Therapeutics

Human Immunodeficiency Virus (HIV)-1 Therapeutics
Market Size is Projected to Experience Significant Growth
from 2017 to 2024.: Global Market Insights Inc.
Human Immunodeficiency Virus Therapeutics Market size should witness tremendous
growth, owing to the sprouting incidence of HIV infections. The growing youth-obsessed
culture across globe is mostly under the vague of HIV due to unprotected sexual
practices coupled with the dearth of awareness concerning transmission risk factors as
well as exposure to contaminated and infected needles or syringes. The collaborative
efforts of the government and various NGOs to provide help for at-risk individuals with
greater receptiveness to disease testing and treatment is the key driving factor of the
human immunodeficiency virus therapeutics market. According to American Hospital
Association, there were 1.5 million adults and children surviving with HIV/AIDS in
North America as of 2016.
High adolescent fertility rate is the opposing effect of extramarital and premarital sex,
leading to longer period of sexual activity which increases the risk of infection among
the populace. The virus has mostly affected the under developed and the developing
countries on a broader scale owing to the scarcity of appropriate treatment, prevention
measures and facilities. Approximately 70,000 children and adults are anew infected
every year. Nearly 26,000 people in North America die from AIDS every year, with only
limited number of patients receive admittance to antiretroviral treatments.
Programs such as Medicare and Medicaid initiated by the U.S. government assists the
low-income people in medical billing. The largest HIV specific discretionary grant
program is the Ryan White HIV Program which serves as the third biggest source of
federal funding for HIV treatment and care in the U.S. The NRTIs (first type of drug
available to treat HIV) accounted for the largest market share. It works by blocking the
reverse transcriptase enzyme as well as arrests viral replication and impede reverse
transcriptase activity.
Integrase inhibitors product segment will witness fastest growth, due to the rise in
added integrase inhibitors by key players such as Merck & Co. and Gilead Sciences.
These enzymes replicate by inserting viral genomic DNA into the host chromosome. The
recent discovery in this segment is the quinoline-based allosteric IN inhibitors
(ALLINIs), which potently impairs HIV-1 replication and are presently in clinical trials.
1 | Page